Coors family creates new medical device company; Globus Medical acquires Transplant Tech;

@FierceMedDev: ICYMI Friday: New microscope offers 3D cellular images that are fast, detailed and low toxicity. Article | Follow @FierceMedDev

@VarunSaxena2: Edwards profit up 23%, but increased TAVR competition looming. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

> A new blood monitoring nanodevice developed at the University of Montreal can rapidly measure optimal and adverse effects in patients being treated with methotrexate, a commonly used but potentially toxic cancer drug. Story

> Musculoskeletal implant manufacturer Globus Medical ($GMED) acquired Transplant Technologies of Texas, a provider of human tissue products, including including bone allografts, biomaterials, and soft tissue products. Release

> Affiliated with the Coors family (known for its famous beer), medical device company CoorsTek Medical officially launched as a company earlier this month. Formerly two companies, the new company will continue to manufacture orthopedic implants and instruments for industry bigwigs like Johnson & Johnson ($JNJ). Story

> Zyga Technology, a medical device company focused on minimally invasive products to treat lumbar spine conditions, received CE mark approval for its Glyder Facet Restoration Device, a long-term surgical treatment for low back pain caused by facet joint degeneration. Release

Biotech News

@FierceBiotech: Sarepta plunges as CEO moves goal line on Duchenne MD drug downfield. Report | Follow @FierceBiotech

@JohnCFierce: Les Echos and Bloomberg both say Viehbacher future in doubt at Sanofi ... among the chief irritants: Viehbacher's move to Boston. | Follow @JohnCFierce

@DamianFierce: Viehbacher's letter to the $SNY board is a wincing read. "Ask Len Schleifer about me!" | Follow @DamianFierce

@EmilyMFierce: Managers of discredited STAP stem cell study refund salary. More from Science | Follow @EmilyMFierce

> Akebia craters as adverse events cloud positive PhIIb anemia data. Article

> INC Research spells out details on $150M IPO. Item

> Pfizer finally abandons all hope in Remoxy, and Durect/Pain Therapeutics feel the sting. Report

Pharma News

@FiercePharma: EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed. ICYMI Friday | Follow @FiercePharma

@EricPFierce: #Novorossiya gets subpoenaed for information about a manufacturing plant in #DenmarkHill. More | Follow @EricPFierce

@CarlyHFierce: Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share. News | Follow @CarlyHFierce

> Novartis unloads last piece of vaccines puzzle to CSL for $275M. Story

> Merck bogged down by slumping sales, but cuts deliver on profits. Article

> Is Viehbacher's job in danger? Some Sanofi directors are agitating for change, says Les Echos. Report

CRO News

> SRI's CRO cuts the ribbon on a new early-phase outpost. Item

> MPI buys out a CRO neighbor to bolster early-stage R&D. More

> CROs line up to advise Big Pharma's R&D think tank. Story

> WuXi teams up with Foundation Medicine to bring cancer profiling to China. Article

> Icon posts another revenue jump and dials up its expectations. Report

Biotech IT News

> Billionaire doc teams with Oxford Uni to build 'NASA of biomedicine.' More

> NIH-funded registry of patient-entered genetic data goes live. News

> 23andMe steps up R&D with new hire, poster push. Report

> Human Longevity backer creates $100M fund for 'crazy' ideas. Story

> Microsoft makes cloud-computing available to Ebola researchers. Article

Animal Health News

> USDA awards $4.5M to vets working in underserved areas. Article

> VCA beats Q3 estimates on same-store hospital sales growth. Report

> Are flea-fighting pills gaining ground on OTC topicals? Item

> K-State, Lawrence Livermore team on Dx tools to detect infectious diseases. Story

> Report: Pet owners jump on the probiotics bandwagon. More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.